RxDoctor Payments Data

Geeta Sangani, MD

Internal Medicine · Syracuse, NYNPI 1992784995

Payments from drug & device makers

$20,571in general payments, 2019–2025

Across 351 payments — averaging $58.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$12K
  • Medtronic$1K
  • Lilly USA, LLC$976
  • Sanofi-aventis U.S. LLC$700
  • Sanofi$407
  • Amgen$403
  • plus $5K from 37 others

What the payments were for

  • Speaking & faculty fees$13,15964%
  • Travel & lodging$8724%
  • Food & beverage$6,51632%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,571 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$147,528
Medicare patients
333
Services billed
3,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide241$412,567
TrulicityDulaglutide112$189,482
JardianceEmpagliflozin91$119,310
ProliaDenosumab54$92,341
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog47$66,435
MounjaroTirzepatide33$62,044
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres11$58,741
FarxigaDapagliflozin Propanediol36$56,341
Fiasp FlextouchInsulin Aspart (Niacinamide)31$30,308
InvokanaCanagliflozin25$28,124
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog34$25,383
Synjardy XrEmpagliflozin/Metformin Hcl23$21,932
Humalog Kwikpen U-100Insulin Lispro57$19,771
EliquisApixaban18$17,181
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$16,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$236$420,169281 claims
Lilly USA, LLCTrulicity, Mounjaro$976$251,526145 claims
Boehringer IngelheimJardiance, Synjardy Xr$199$141,242114 claims
AmgenProlia$403$92,34154 claims
NovartisSandostatin Lar Depot$66$58,74111 claims
AstraZenecaFarxiga$333$56,34136 claims
Johnson & JohnsonInvokana$12,183$28,12425 claims
PfizerEliquis$294$17,18118 claims
AbbVieSynthroid$248$15,427192 claims
MerckJanuvia$177$15,12513 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$120$11,213706 claims
GSKBreo Ellipta$74$6,23516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →